Thursday, October 30, 2014

Roth names John Chambers as vice chairman

Roth names John Chambers as vice chairman

October 30, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has named John Chambers as vice chairman in addition to his ongoing role as head of healthcare investment banking, a position he has held since joining Roth 2009. Mr. Chambers and his team has assisted Roth’s healthcare clients in raising over $8-billion in approximately 220 transactions since 2009. “John is an […]

BiondVax gets patent approvals in EU and Japan

BiondVax gets patent approvals in EU and Japan

October 29, 2014 by · Leave a Comment 

Tweet BiondVax Pharmaceuticals (TASE:BNDX), which is developing a universal flu vaccine, has received approvals from the European Union and from Japan’s patent authorities for its patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family. The patent family covers vaccination against influenza in humans and specifically, vaccines that confer a long-lasting protection against multiple flu strains. […]

Knight invests $30-million in Teralys fund


Knight invests $30-million in Teralys fund


October 29, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has invested $30-million into Teralys Capital Innovation Fund, which is managed by Teralys Capital. Teralys is the largest venture capital fund manager dedicated to technologies and life sciences in Canada, with $1.3-billion in assets under management and a significant focus on the North American life sciences sector. Knight previously invested $13-million […]

Leerink starts Dermira at outperform

Leerink starts Dermira at outperform

October 28, 2014 by · Leave a Comment 

Tweet Leerink Partners has initiated coverage of Dermira (NASDAQ:DERM) with an “outperform” rating and a $32 price target based on a discounted cash flow analysis. The stock closed at $15.50 on Monday. Dermira is a development stage specialty pharmaceutical company focused exclusively on advancing therapeutics used by dermatologists to treat skin-related conditions. Analyst Seamus Fernandez writes […]

Ciclofilin Pharma names Stephen Keane as SVP

Ciclofilin Pharma names Stephen Keane as SVP

October 27, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals has named Stephen Keane as SVP of corporate development, with responsibility for structuring, negotiating and executing strategic alliances and co-development agreements. Mr. Keane brings over 25 years of experience to Ciclofilin. He has held key leadership positions with leading life sciences companies, including Staurus Pharmaceuticals, Femta Pharmaceuticals, Ambit Biosciences, Cosmo […]

HCW starts TG Therapeutics at buy

HCW starts TG Therapeutics at buy

October 27, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of TG Therapeutics (NASDAQ:TGTX) with a “buy” rating and target price of $17, based on discounted revenue and earnings per share valuation methodology. The stock closed at $10.89 on Friday. TG’s core franchise is comprised of a glycol-engineered, anti-CD20 monoclonal antibody and a novel PI3Kδ inhibitor, targeting B cell […]

Stellar in KLH supply pact with Biovest

Stellar in KLH supply pact with Biovest

October 23, 2014 by · Leave a Comment 

Tweet Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) and Biovest International have executed a definitive supply agreement to meet Biovest’s requirements for Keyhole Limpet Hemocyanin (KLH) for use in its BiovaxID active immunotherapy to treat follicular non-Hodgkin’s lymphoma. BiovaxID combines autologous heterohybridoma-derived tumor idiotype protein coupled to KLH as the carrier molecule. BiovaxID has successfully completed Phase 2 […]

HCW starts Advaxis at buy

HCW starts Advaxis at buy

October 23, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and $8 price target. The stock closed at $2.84 on Wednesday. Advaxis’ strategy is to monetize a novel platform and to enter into partnerships to become a major player in the cancer immunotherapy market, writes analyst Swayampakula Ramakanth. The company’s platform utilizes […]

Nuvo sees $1-billion in peak yearly WF10 sales

Nuvo sees $1-billion in peak yearly WF10 sales

October 22, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) has released the results of a market study that forecasts its WF10 treatment could capture 10% to 15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of $700-million to $1.1-billion. The study was preformed by Psscion Lifesciences Consulting to investigate the U.S. opportunity for WF10, an experimental […]

NOVADAQ inks Japan distribution deal with Mizuho

NOVADAQ inks Japan distribution deal with Mizuho

October 21, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into an exclusive five-year agreement with Mizuho Corporation for the distribution of NOVADAQ’s PINPOINT Endoscopic Fluorescence Imaging System in Japan. “The agreement with Mizuho  further strengthens our ability to achieve growth through our commitment to globalization,” Dr. Arun Menawat, president and CEO of NOVADAQ, said in a statement. Mizuho currently […]

Next Page »

Email Newsletters with Constant Contact
Google+